Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone

Psychopharmacology

Volumn 147, Issue 3, 1999, Pages 300-305

  Scordo, Maria Gabriella ^a,b   Spina, Edoardo ^a,c   Facciolà, Gabriella ^a   Avenoso, Angela ^a   Johansson, Inger ^d   Dahl, Marja Liisa ^b  

^a UNIVERSITY OF MESSINA   (Italy)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c ASL 5   (Italy)

^d KAROLINSKA INSTITUTE   (Sweden)

Author keywords

9 hydroxyrisperidone; CYP2D6 genotype; Genetic polymorphism; Risperidone; Steady state plasma concentration

Indexed keywords

DEBRISOQUINE 4 HYDROXYLASE; PALIPERIDONE; RISPERIDONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; ENZYME POLYMORPHISM; FEMALE; GENETIC ANALYSIS; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; STEADY STATE;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; FEMALE; GENOTYPE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PYRIMIDINES; RISPERIDONE; SCHIZOPHRENIA;

EID: 0033987060     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002130051171     Document Type: Article

References (37)

1. Agúndez JAG, Ledesma MC, Ladero JM, Benitez J (1995) Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin Pharmacol Ther 57:265-269
2. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446
3. Alván G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39:533-537
4. Bertilsson L, Dahl ML (1996) Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 5:200-223
5. Bertilsson L, Dahl M-L, Sjöqvist F, Åberg-Wistedt A, Humble M, Johansson I, Lundqvist E, Ingelman-Sundberg M (1993) Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341:63
6. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, Meyer UA (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10:545-558
7. Chouinard G, Arnott W (1993) Clinical review of risperidone. Can J Psychiatry 38:89-95
8. Dahl M-L, Ekqvist B, Widén J, Bertilsson L (1991) Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand 84:99-102
9. Dahl M-L, Johansson I, Porsmyr Palmertz M, Ingelman-Sundberg M, Sjöqvist F (1992) Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin Pharmacol Ther 51:12-17
10. Dahl M-L, Johansson I, Bertilsson L, Ingelman-Sundberg M, Sjöqvist F (1995) Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J Pharmacol Exp Ther 274:516-520
11. Dahl-Puustinen M-L, Liden A, Alm C, Bertilsson L (1989) Disposition of perphenazine is related to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 46:78-81
12. Daly AK, Armstrong M, Monkman SC, Idle JR (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1:33-41
13. Darby JK, Pasta DJ, Elfand L, Dabiri L, Clark L, Herbert J (1997) Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol 17:478-484
14. De Leon J, Bork J (1997) Risperidone and cytochrome P4503A. J Clin Psychiatry 58:450
15. Eichelbaum M, Spannbrucker N, Steincke B, Dengler JH (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 16:183-187
16. Evans DAP, Mahgoub A, Sloan TP, Idle JR, Smith RL (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17:102-105
17. Heim M, Meyer UA (1990) Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336:529-532
18. Huang ML, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AAJ, Zylicz Z, Visscher HW, Jonkman JHG (1993) Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 54:257-268
19. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M (1993) Inherited amplification of an active gene in the cytochrome P450 2D-locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 90:11825-11829
20. Johansson I, Lundqvist E, Dahl M-L, Ingelman-Sundberg M (1996) PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics 6:351-355
21. Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247:661-670
22. LLerena A, Alm C, Dahl ML, Ekqvist B, Widén J, Bertilsson L (1992) Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit 14:261-264
23. Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584-586
24. Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J (1993) Absorption, metabolism and excretion of risperidone in humans. Drug Metab Dispos 21:1134-1141
25. Meyer JW, Woggon B, Baumann P, Meyer UA (1990) Clinical implications of slow sulphoxidation of thioridazine in a poor metabolizer of the debrisoquine type. Eur J Clin Pharmacol 39:613-614
26. 2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology 119:345-348
27. Olesen OV, Linnet K (1997) Simplified high-performance liquid chromatographic method for determination of risperidone and 9-hydroxyrisperidone in serum from patients comedicated with other psychotropic drugs. J Chromatogr B Biomed Appl 698:209-216
28. Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit 20:380-384
29. Perucca E, Richens A (1995) Biotransformation. In: Levy RH, Mattson RH, Meldrum BS (eds) Antiepileptic drugs, 4th edn. Raven Press, New York, pp 31-50
30. Sachse C, Brockmöller J, Bauer S, Roots I (1997) Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284-295
31. Saxena R, Shaw GL, Relling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B (1994) Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 3:923-926
32. Spina E, Buemi AL, Sanz E, Bertilsson L (1989) Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests. Ther Drug Monit 11:721-723
33. Spina E, Ancione M, Di Rosa AE, Meduri M, Caputi AP (1992) Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol 42:347-348
34. Steiner E, Iselius L, Alván G, Lindsten J, Sjöqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clin Pharmacol Ther 38:394-401
35. Tucker GT, Silas JH, Iyun AO, Lennard M, Smith AJ (1977) Polymorphic hydroxylation of debrisoquine. Lancet 2:718
36. Van Beijsterveldt LEC, Geerts RJF, Leysen JE, Megens AAHP, Van den Eynde HMJ, Meuldermans WEG, Heykants JJP (1994) The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat. Psychopharmacology 114:53-62
37. von Bahr C, Movin G, Nordin C, Lidén A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sjöqvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquine hydroxylation phenotype. Clin Pharmacol Ther 49:234-240